Hinge Health (NYSE:HNGE) Sees Large Volume Increase Following Better-Than-Expected Earnings

Shares of Hinge Health Inc. (NYSE:HNGE) saw an uptick in trading volume on Tuesday after the company announced better than expected quarterly earnings. 1,456,380 shares traded hands during trading, an increase of 30% from the previous session’s volume of 1,123,016 shares.The stock last traded at $50.3360 and had previously closed at $48.89.

The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.33. The business had revenue of $182.31 million for the quarter. Hinge Health had a negative return on equity of 279.39% and a negative net margin of 78.95%.The business’s revenue for the quarter was up 47.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.30 earnings per share.

Key Hinge Health News

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Q1 beat and improved outlook: Hinge reported a strong Q1 with revenue up ~47%, EPS above estimates and margin expansion; management raised 2026 guidance, which drove a sharp post‑earnings rally. HNGE Stock Up on Q1 Earnings & Revenue Beat
• Positive Sentiment: Raised 2026 outlook and condition expansion: Company lifted its 2026 outlook after strong Q1 execution and announced expansion into additional conditions, supporting revenue diversification and longer-term growth prospects. Hinge Health lifts 2026 outlook after strong Q1
• Positive Sentiment: Product launch & revenue guide: Hinge forecasted $798M–$804M for 2026 and announced the FDA‑cleared Enso migraine program launch — a new commercial opportunity that could expand addressable market and revenue per client. Hinge Health forecasts 2026 revenue and launches Enso migraine
• Positive Sentiment: Analyst upward revisions: Multiple brokerages raised price targets and ratings this morning (Wells Fargo, Citizens JMP, Stifel, Needham), signaling stronger sell‑side conviction and adding buying interest. Benzinga coverage of upgrades The Fly coverage
• Neutral Sentiment: Earnings call details available: Full Q1 2026 earnings call transcript was published for investors wanting the management commentary on guidance drivers, sales pipeline and margin cadence. Q1 2026 Earnings Call Transcript
• Negative Sentiment: Profitability still a watch item: despite the beat, the company remains unprofitable on a net‑margin and ROE basis; investors should watch margin trajectory and cash flow conversion as growth scales. Background data

Wall Street Analyst Weigh In

A number of equities analysts have commented on HNGE shares. Evercore reissued an “outperform” rating and issued a $45.00 price objective on shares of Hinge Health in a research note on Wednesday, April 8th. Wall Street Zen lowered Hinge Health from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Citizens Jmp boosted their price objective on Hinge Health from $65.00 to $80.00 and gave the stock a “market outperform” rating in a research note on Wednesday. Barclays raised their price target on Hinge Health from $52.00 to $62.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Citigroup restated an “outperform” rating on shares of Hinge Health in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $67.40.

Insider Transactions at Hinge Health

In related news, CEO Daniel Antonio Perez sold 166,665 shares of the stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $40.26, for a total transaction of $6,709,932.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Gabriel M.I. Mecklenburg sold 166,666 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $45.32, for a total value of $7,553,303.12. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 442,670 shares of company stock valued at $18,786,901 in the last ninety days. Corporate insiders own 18.92% of the company’s stock.

Institutional Investors Weigh In On Hinge Health

Several hedge funds have recently bought and sold shares of the stock. BIT Capital GmbH lifted its position in Hinge Health by 79.3% during the fourth quarter. BIT Capital GmbH now owns 3,316,101 shares of the company’s stock worth $154,033,000 after acquiring an additional 1,466,577 shares during the last quarter. Vanguard Group Inc. lifted its position in Hinge Health by 110.5% during the fourth quarter. Vanguard Group Inc. now owns 2,605,532 shares of the company’s stock worth $121,027,000 after acquiring an additional 1,367,693 shares during the last quarter. Tiger Global Management LLC lifted its position in Hinge Health by 227.1% during the fourth quarter. Tiger Global Management LLC now owns 1,805,751 shares of the company’s stock worth $83,877,000 after acquiring an additional 1,253,743 shares during the last quarter. Millennium Management LLC lifted its position in Hinge Health by 225.0% during the fourth quarter. Millennium Management LLC now owns 1,479,642 shares of the company’s stock worth $68,729,000 after acquiring an additional 1,024,317 shares during the last quarter. Finally, Braidwell LP lifted its position in Hinge Health by 43.3% during the fourth quarter. Braidwell LP now owns 1,304,623 shares of the company’s stock worth $60,600,000 after acquiring an additional 394,147 shares during the last quarter.

Hinge Health Price Performance

The business’s 50-day moving average is $42.81 and its 200 day moving average is $44.00. The firm has a market capitalization of $4.33 billion and a P/E ratio of -4.45.

Hinge Health Company Profile

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.